Our discovery platform has led to the identification and validation of surface antigens associated with cancer for use in therapeutic , vaccine and drug development, as well as diagnostic imaging. Targets are made available through various partnering and out-licensing structures, with a goal of enabling both early and late-stage drug development programs. These relationships provide novel targets for our partners and the opportunity for Celera to recognize longer term value in the form of milestone payments and royalties.
Our development programs have been partnered to provide Celera with the potential for future returns on our earlier investments in drug discovery. Of these, the Cathepsin K inhibitor program currently in Phase 3 clinical trials for osteoporosis at Merck is most advanced.